Results 201 to 210 of about 958,890 (240)

JAK-STAT signaling maintains homeostasis in T cells and macrophages

Nature Immunology
Immune cells need to sustain a state of constant alertness over a lifetime. Yet, little is known about the regulatory processes that control the fluent and fragile balance that is called homeostasis.
N. Fortelny, Matthias Farlik, Victoria Fife, A. Gorki, C. Lassnig, B. Maurer, Katrin Meissl, Marlies Dolezal, Laura Boccuni, Aarathy Ravi Sundar Jose Geetha, Mojoyinola Joanna Akagha, Anzhelika Karjalainen, Stephen Shoebridge, Asma Farhat, Ulrike Mann, Rohit Jain, Shweta Tikoo, N. Zila, Wolfgang Esser-Skala, Thomas Krausgruber, K. Sitnik, T. Penz, A. Hladik, Tobias Suske, S. Zahalka, M. Senekowitsch, D. Barreca, F. Halbritter, Sabine Macho-Maschler, W. Weninger, H. Neubauer, R. Moriggl, Sylvia Knapp, Veronika Sexl, B. Strobl, Thomas Decker, Mathias Müller, Christoph Bock   +37 more
semanticscholar   +1 more source

Selective JAK Inhibitors

Future Medicinal Chemistry, 2014
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock, Eugene Guorong, Yang, Yuyi, Chu-Farseeva, Lianbin, Yao   +3 more
openaire   +2 more sources

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Science, 1994
J. Darnell, I. Kerr, George Stark Stark
semanticscholar   +1 more source

Myśleć jak filozof, argumentować jak kognitywista

2005
Diametros, No 3 (2005)
openaire   +1 more source

JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

Nature reviews: Gastroenterology & hepatology, 2020
A. Salas, Cristian Hernandez-Rocha, M. Duijvestein, W. Faubion, D. McGovern, S. Vermeire, S. Vetrano, N. Vande Casteele   +7 more
semanticscholar   +1 more source

The role of JAK/STAT signaling pathway and its inhibitors in diseases.

International Immunopharmacology, 2020
Ping Xin, Xiaoyun Xu, Chengjie Deng, Shuang Liu, Youzhi Wang, Xuegang Zhou, Hongxing Ma, Donghua Wei, Shiqin Sun   +8 more
semanticscholar   +1 more source

[JAK inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2013
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire   +1 more source

Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician

Nature Reviews Rheumatology
Zoltán Szekanecz, M. Buch, C. Charles-Schoeman, J. Galloway, G. Karpouzas, L. E. Kristensen, S. Ytterberg, A. Hamar, Roy M Fleischmann   +8 more
semanticscholar   +1 more source

JAK inhibitor selectivity: new opportunities, better drugs?

Nature Reviews Rheumatology
A. Virtanen, F. R. Spinelli, J. Telliez, John J O'Shea, O. Silvennoinen, Massimo Gadina   +5 more
semanticscholar   +1 more source

JAK

2006
openaire   +2 more sources